A predictive model of varicella-zoster vires infection after autologous peripheral blood progenitor cell transplantation

M. Offidani, L. Corvatta, A. Olivieri, A. Mele, M. Brunori, M. Montanari, S. Rupoli, P. Scalari, P. Leoni

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Varicella-zoster virus (VZV) frequently causes severe infections in patients who have undergone bone marrow transplantation. The frequency of, characteristics of, and risk factors for this infection were studied in 164 patients undergoing autologous peripheral blood progenitor cell transplantation (PBPCT). Twenty-six patients (15.8%) developed VZV infection, and the actuarial risk was 10% at 1 year. No patient had visceral dissemination or died because of VZV, although one-third of the patients developed postherpetic neuralgia. By multivariate analysis, a CD4+ lymphocyte count of + lymphocyte count of + and CD8+ lymphocytes are at high risk of VZV infection. These patients should be considered as candidates for preventive therapy, but whether for antiviral therapy or vaccination remains to be investigated.

Original languageEnglish
Pages (from-to)1414-1422
Number of pages9
JournalClinical Infectious Diseases
Volume32
Issue number10
DOIs
Publication statusPublished - May 15 2001

Fingerprint

Chickenpox
Cell Transplantation
Herpes Zoster
Blood Cells
Human Herpesvirus 3
Stem Cells
Infection
Virus Diseases
Postherpetic Neuralgia
Lymphocyte Count
CD4 Lymphocyte Count
Bone Marrow Transplantation
Antiviral Agents
Vaccination
Multivariate Analysis
Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Offidani, M., Corvatta, L., Olivieri, A., Mele, A., Brunori, M., Montanari, M., ... Leoni, P. (2001). A predictive model of varicella-zoster vires infection after autologous peripheral blood progenitor cell transplantation. Clinical Infectious Diseases, 32(10), 1414-1422. https://doi.org/10.1086/320157

A predictive model of varicella-zoster vires infection after autologous peripheral blood progenitor cell transplantation. / Offidani, M.; Corvatta, L.; Olivieri, A.; Mele, A.; Brunori, M.; Montanari, M.; Rupoli, S.; Scalari, P.; Leoni, P.

In: Clinical Infectious Diseases, Vol. 32, No. 10, 15.05.2001, p. 1414-1422.

Research output: Contribution to journalArticle

Offidani, M, Corvatta, L, Olivieri, A, Mele, A, Brunori, M, Montanari, M, Rupoli, S, Scalari, P & Leoni, P 2001, 'A predictive model of varicella-zoster vires infection after autologous peripheral blood progenitor cell transplantation', Clinical Infectious Diseases, vol. 32, no. 10, pp. 1414-1422. https://doi.org/10.1086/320157
Offidani, M. ; Corvatta, L. ; Olivieri, A. ; Mele, A. ; Brunori, M. ; Montanari, M. ; Rupoli, S. ; Scalari, P. ; Leoni, P. / A predictive model of varicella-zoster vires infection after autologous peripheral blood progenitor cell transplantation. In: Clinical Infectious Diseases. 2001 ; Vol. 32, No. 10. pp. 1414-1422.
@article{4e9d72e5e6414e6783dc8140bb9631e5,
title = "A predictive model of varicella-zoster vires infection after autologous peripheral blood progenitor cell transplantation",
abstract = "Varicella-zoster virus (VZV) frequently causes severe infections in patients who have undergone bone marrow transplantation. The frequency of, characteristics of, and risk factors for this infection were studied in 164 patients undergoing autologous peripheral blood progenitor cell transplantation (PBPCT). Twenty-six patients (15.8{\%}) developed VZV infection, and the actuarial risk was 10{\%} at 1 year. No patient had visceral dissemination or died because of VZV, although one-third of the patients developed postherpetic neuralgia. By multivariate analysis, a CD4+ lymphocyte count of + lymphocyte count of + and CD8+ lymphocytes are at high risk of VZV infection. These patients should be considered as candidates for preventive therapy, but whether for antiviral therapy or vaccination remains to be investigated.",
author = "M. Offidani and L. Corvatta and A. Olivieri and A. Mele and M. Brunori and M. Montanari and S. Rupoli and P. Scalari and P. Leoni",
year = "2001",
month = "5",
day = "15",
doi = "10.1086/320157",
language = "English",
volume = "32",
pages = "1414--1422",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "NLM (Medline)",
number = "10",

}

TY - JOUR

T1 - A predictive model of varicella-zoster vires infection after autologous peripheral blood progenitor cell transplantation

AU - Offidani, M.

AU - Corvatta, L.

AU - Olivieri, A.

AU - Mele, A.

AU - Brunori, M.

AU - Montanari, M.

AU - Rupoli, S.

AU - Scalari, P.

AU - Leoni, P.

PY - 2001/5/15

Y1 - 2001/5/15

N2 - Varicella-zoster virus (VZV) frequently causes severe infections in patients who have undergone bone marrow transplantation. The frequency of, characteristics of, and risk factors for this infection were studied in 164 patients undergoing autologous peripheral blood progenitor cell transplantation (PBPCT). Twenty-six patients (15.8%) developed VZV infection, and the actuarial risk was 10% at 1 year. No patient had visceral dissemination or died because of VZV, although one-third of the patients developed postherpetic neuralgia. By multivariate analysis, a CD4+ lymphocyte count of + lymphocyte count of + and CD8+ lymphocytes are at high risk of VZV infection. These patients should be considered as candidates for preventive therapy, but whether for antiviral therapy or vaccination remains to be investigated.

AB - Varicella-zoster virus (VZV) frequently causes severe infections in patients who have undergone bone marrow transplantation. The frequency of, characteristics of, and risk factors for this infection were studied in 164 patients undergoing autologous peripheral blood progenitor cell transplantation (PBPCT). Twenty-six patients (15.8%) developed VZV infection, and the actuarial risk was 10% at 1 year. No patient had visceral dissemination or died because of VZV, although one-third of the patients developed postherpetic neuralgia. By multivariate analysis, a CD4+ lymphocyte count of + lymphocyte count of + and CD8+ lymphocytes are at high risk of VZV infection. These patients should be considered as candidates for preventive therapy, but whether for antiviral therapy or vaccination remains to be investigated.

UR - http://www.scopus.com/inward/record.url?scp=0035873217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035873217&partnerID=8YFLogxK

U2 - 10.1086/320157

DO - 10.1086/320157

M3 - Article

VL - 32

SP - 1414

EP - 1422

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 10

ER -